The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 2 trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in subjects with metastatic pancreatic cancer.
Dung T. Le
No relevant relationships to disclose
Daniel A. Laheru
No relevant relationships to disclose
Katrina Purtell
No relevant relationships to disclose
Jennifer N. Uram
No relevant relationships to disclose
Hao Wang
No relevant relationships to disclose
Susie Lawrence
No relevant relationships to disclose
Rose Parkinson
No relevant relationships to disclose
Ellen-Lilly Foreman
No relevant relationships to disclose
Dionne T Savage
No relevant relationships to disclose
Jacob Joseph-David
No relevant relationships to disclose
Ross C. Donehower
No relevant relationships to disclose
Zeshaan Rasheed
No relevant relationships to disclose
Lei Zheng
No relevant relationships to disclose
Nilofer Saba Azad
No relevant relationships to disclose
David Cosgrove
No relevant relationships to disclose
Ana De Jesus-Acosta
No relevant relationships to disclose
Ilene S. Browner
No relevant relationships to disclose
Luis A. Diaz
No relevant relationships to disclose